



9th April, 2025

<p>To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701 (Equity) : 974556, 975834 and 976560 (Debt)</p>	<p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – EQ</p>
---	--

SUB: DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS, 2015: COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD., RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SITE, CHINA

Dear Sir,

With reference to the captioned subject, we are pleased to inform you that yesterday the Company’s wholly owned subsidiary namely CARBOGEN AMCIS (Shanghai) Co. Ltd., has received Drug Manufacturing License from the National Medical Product Administration (NMPA) for its Shanghai, China.

Kindly take this on your record.

Thanking you.

Yours faithfully,
For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary